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fetal circulatory support (fetal cardiac bypass) safely and
reliably. Previous studies have shown that the major hin-
drance to fetal cardiac bypass is peribypass placental
dysfunction, which is characterized by elevated placen-
tal vascular resistance (PVR), decreased placental blood
F or certain complex congenital heart defects, fetal car-diac surgery may yield significantly better results
than can be achieved with standard methods of neonatal
and infant repair.1 A prerequisite for successful fetal car-
diac surgery is the ability to maintain extracorporeal
Background: Fetal cardiac bypass causes placental dysfunction, charac-
terized by increased placental vascular resistance, decreased placental
blood flow, hypoxia, and acidosis. Vasoactive factors produced by the
vascular endothelium, such as nitric oxide and endothelin 1, are impor-
tant regulators of placental vascular tone and may contribute to this
placental dysfunction. Methods: To investigate the role of the vascular
endothelium in placental dysfunction related to fetal cardiac bypass, we
studied 3 groups of fetal sheep. In the first group (n = 7) we determined
placental hemodynamic responses before and after bypass to an
endothelium-dependent vasodilator (acetylcholine), an endothelium-
independent vasodilator (nitroprusside), and endothelin 1. In the second
group (n = 8) a nonspecific endothelin receptor blocker (PD 145065) was
administered and placental hemodynamic values were measured before
and after bypass. In the third group (n = 5) endothelin 1 levels were
measured before and after bypass. Results: Before fetal cardiac bypass
exogenous endothelin 1 decreased placental blood flow by 9% and
increased placental resistance by 9%. After bypass endothelin 1
decreased placental flow by 47% and increased resistance by 106%.
There was also a significant attenuation of the placental vascular relax-
ation response to acetylcholine after bypass, whereas the response to
nitroprusside was not significantly altered. In fetuses that received the
PD 145065, placental vascular resistance increased significantly less
than in control fetuses (28% versus 62%). Similarly, placental blood
flow decreased significantly more (from 6.3 ± 3.1 to 28.3 ± 10.4 pg/mL;
P = .01) in control fetuses than in fetuses receiving PD 145065 (33% ver-
sus 20%). Umbilical venous endothelin 1 levels increased significantly in
fetuses exposed to fetal bypass but did not change in control fetuses.
Conclusions: The basal endothelial regulatory mechanisms of placental
vascular tone were deranged after fetal cardiac bypass. Endothelin
receptor blockade, which substantially reduced postbypass placental
dysfunction, and other interventions aimed at preserving endothelial
function may be effective means of optimizing fetal outcome after car-
diac bypass. (J Thorac Cardiovasc Surg 1999;117:343-51)
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flow (PBF), acidosis, hypoxia, and hypercarbia.2-4 A
number of mechanisms of bypass-related placental dys-
function have been found, and various interventions
have been shown to improve hemodynamics and gas
exchange during and after fetal cardiac bypass.2-6
One potentially important aspect of fetoplacental cir-
culatory physiology and bypass-related placental dys-
function that has not been studied extensively is the role
of placental endothelial function. The placental vascula-
ture is thought to be maximally dilated in the basal
state.7 Recent evidence indicates that nitric oxide8-10
and endothelin 1 (ET-1)11-13 are important regulators of
placental vascular tone. Endothelial factors such as
these may therefore have a role in the placental dys-
function that has been observed to occur during and
after fetal cardiac bypass.6 In this study we performed a
series of experiments to address this dimension of pla-
cental pathophysiology after fetal cardiac bypass.
Methods
To investigate the role of the vascular endothelium in pla-
cental dysfunction related to fetal cardiac bypass, we studied
3 groups of fetal sheep. In the first (group 1, n = 7), we inves-
tigated the effect of bypass on placental endothelial function
by comparing hemodynamic responses before and after fetal
bypass to an endothelium-dependent vasodilator (acetyl-
choline), an endothelium-independent vasodilator (sodium
nitroprusside), and ET-1, a vasoactive polypeptide produced
by the endothelium. In the second group (group 2, n = 8) the
role of endogenous ET-1 in bypass-related placental dysfunc-
tion was assessed by comparing placental hemodynamics
before and after bypass between 8 fetuses administered an
ET-1 receptor blocker (PD 145065) and 5 control fetuses that
did not receive PD 145065. In the third group (group 3, n =
5) the aim was to determine whether the circulating level of
endogenous ET-1 was affected by fetal cardiac bypass. No
medications were given and umbilical venous ET-1 levels
were measured before and after fetal cardiac bypass. ET-1
levels and hemodynamics were also measured in 4 control
fetuses that had instruments placed and were exposed in an
identical fashion but were not placed on bypass.
Surgical preparation and fetal cardiac bypass. Anes-
thesia, operation, and fetal cardiac bypass were performed as
previously described at 118 to 122 days’ gestation in singleton
or twin fetuses carried by mixed-breed pregnant ewes.14 After
anesthesia and exposure of the fetus, a fetal flank incision was
made to allow placement of a number 6 S series ultrasonic
perivascular flow probe (Transonic Systems Inc, Ithaca, NY)
around the common umbilical artery for continuous monitor-
ing of PBF. A 20-gauge arterial catheter was placed into the
descending aorta 1 inch proximal to the common umbilical
artery and secured. The flow probe and arterial line were
brought outside and the fetal incision and hysterotomy were
closed. The fetal chest was exposed through a second hystero-
tomy. Fetal electrocardiographic leads were placed to monitor
the heart rate. A jugular venous line was placed to administer
intravenous fluids and monitor fetal central venous pressure.
Fetal temperature was monitored with a temperature probe
placed in the fetal peritoneal cavity, and temperatures were
maintained above 36°C at all times by wrapping the uterus in
a thermal heating blanket (40°C) and intermittently pouring
warm saline solution over the fetus and uterus.
Midline fetal sternotomy and pericardiotomy were per-
formed and the heart was exposed. The main pulmonary artery
and the ascending aorta were dissected. and perivascular flow
probes were placed around the main pulmonary artery (num-
ber 8 S probe) and the aorta (number 6 S probe) for continu-
ous monitoring of the combined ventricular output.
The fetus underwent anticoagulation with 300 units/kg
heparin administered through the superior vena cava. The
right atrium was cannulated through the superior vena cava
with a 16F angled-tip venous cannula, and the bypass circuit
was filled with fetal blood and cleared of air. The main pul-
monary artery was cannulated with a 12F arterial cannula,
which was then filled with fetal blood and cleared of air. The
arterial and venous cannulas were connected with 0.25-inch
polyvinyl tubing to a previously described bypass circuit,14
which uses an in-line axial flow pump (Hemopump, modified
model HP24 sternotomy pump; Medtronic Inc, Grand
Rapids, Mich) and an in-line flow probe. Bypass was initiat-
ed. During bypass the flow probe was removed from the main
pulmonary artery because flow in this vessel was equal to
pump flow. Backflow from the main pulmonary artery into
the ventricle and backflow from the ventricle into the main
pulmonary artery were prevented by crossclamping the artery
just above the pulmonary valve, proximal to the cannulation
site.
Because of the need for high flows when the placenta is
incorporated into the circulation for oxygenation, pump flows
were maintained at the maximum achievable flow in each
animal (generally about 250-300 mL · kg–1 · min–1). Pump
flows were monitored continuously with the in-line flow
probe. After 30 minutes of bypass the cannulas were
removed, the condition of the fetus was allowed to stabilize
for 15 minutes, and the study was resumed. After completion
of the study the ewes and fetuses were killed by an overdose
of intravenous pentobarbital. The dead fetuses were delivered
and an autopsy was performed to confirm the positions of all
vascular catheters. The amniotic fluid was dried and the
fetuses were weighed.
All animals received humane care in compliance with the
“Principles of Laboratory Animal Care” formulated by the
National Society of Medical Research and the “Guide for the
Care and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources and published by
the National Institutes of Health (NIH Publication No. 86-23,
revised 1985). The experimental protocol was approved by
the Committee for Animal Care at the University of
California, San Francisco.
Experimental protocol
Group 1. Acetylcholine chloride (Iolab Corp, Claremont,
Calif) was diluted in sterile 0.9% saline solution. Sodium
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nitroprusside (Abbott Laboratories, Chicago, Ill) was diluted
in 5% dextrose in water. ET-1 (0.5 mg, MW 2491.1; Peptides
International, Inc, Louisville, Ky) was resuspended in 10 mL
sterile water and stored at –20°C. All solutions were prepared
on the day of the study.
After exposure of and placement of instrumentation in the
fetuses but before cardiac bypass, the following pharmaco-
logic interventions were performed, in random order: acetyl-
choline (1 m g/kg bolus), nitroprusside (1 m g · kg–1 · min–1
infusion), and ET-1 (125 ng/kg bolus). Between each inter-
vention hemodynamic and blood gas variables were moni-
tored, and the next intervention was performed only after all
variables had returned to baseline and stabilized. After fetal
cardiac bypass the conditions of fetuses were allowed to sta-
bilize for at least 15 minutes. At this point the aforementioned
pharmacologic interventions were performed again, in ran-
dom order.
Group 2. After placement of instrumentation in the fetus
but before initiation of fetal cardiac bypass, an infusion of PD
145065, a nonselective endothelin receptor blocker (50 m g ·
kg–1 · min–1, synthesized by the Medicinal Chemistry De-
partment; Parke-Davis Pharmaceutical Research, Ann Arbor,
Mich), was started.15 Thirty minutes was allowed to elapse
and fetoplacental hemodynamics before bypass were record-
ed; after that, bypass was initiated. The PD 145065 infusion
was continued during the entire period of fetal cardiac bypass
and throughout the postbypass study period. The dose of PD
145065 was chosen on the basis of a previous study, which
showed that a 30-minute infusion completely blocked the
vasoconstrictive effects of exogenous ET-1.16 After discon-
tinuation of bypass the conditions of fetuses were allowed to
stabilize, and postbypass hemodynamic measurements were
recorded 30 minutes after bypass. To document that PD
145065 had completely antagonized ET-1, a bolus of exoge-
nous ET-1 was administered at 60 minutes after bypass in
twice the dose as that used in group 1 (250 ng/kg) and the
hemodynamic response was recorded. In control animals the
same protocol was used, but crystalloid solution (Normosol,
pH 7.4; Abbott Laboratories) was infused instead of PD
145065, at the same rate.
Group 3. In this group no medications were given and plas-
ma ET-1 levels were measured before and 15 minutes after
bypass. ET-1 levels were measured from 4 mL umbilical
venous blood according to a previously described assay.17
The blood was placed in iced polypropylene tubes containing
100 m L ethylenediaminetetraacetic acid and 330 m L aprotinin
and then immediately centrifuged at 4000g for 20 minutes.
The plasma was treated with an equal volume of 0.1% triflu-
oroacetic acid and stored at –70°C. The acidified supernatant
was centrifuged at 1000g for 20 minutes and loaded on a 3 ·
18 C18 Sep-Pak column (Peninsula Laboratories, Belmont,
Calif) equilibrated with 0.1% trifluoroacetic acid. The
adsorbed material was eluted with 3 mL 0.1% trifluoroacetic
acid and 60% acetonitrile. The eluant was dried and stored at
–70°C or assayed immediately for immunoreactive ET-1. ET-
1 standard, ET-1 labeled with iodine 125, antiendothelin anti-
body, and secondary antibody were purchased from
Peninsula Laboratories. Cross-reactivities for measured
human and bovine ET-1 antiserum were 100% for human ET-
1, 7% for human endothelins 2 and 3, and 0% for bovine
endothelins 2 and 3. Each sample was assayed twice, and the
average of the 2 runs was recorded for analysis.
Hemodynamic monitoring. Systemic arterial pressure
(SAP) and central venous pressure were measured with
Statham P23Db pressure transducers (Statham Instruments,
Hato Rey, Puerto Rico). Mean pressures were obtained by
means of electrical integration. Heart rate was measured with
a cardiotachometer triggered by the phasic SAP pulse wave.
Flows were measured with ultrasonic flowmeters (Transonic
Systems). All hemodynamic variables were recorded contin-
uously on a Gould multichannel electrostatic recorder (model
TA11; Gould Inc, Cleveland, Ohio). Fetal and maternal arte-
rial blood gas and pH values were measured on a Corning
158 pH/blood gas analyzer (Corning Medical and Scientific,
Medfield, Mass).
Maternal and fetal heart rates, central venous pressure, and
SAP were recorded continuously during the entire study.
Fetal combined ventricular output and PBF were also moni-
tored continuously. In group 1 baseline hemodynamic values
were recorded before each intervention (preintervention val-
ues), and postintervention values were recorded at the point
of maximum effect, usually within 2 minutes of drug admin-
istration. In group 2 prebypass hemodynamic values were
recorded after 30 minutes of PD 145065 infusion. Maternal
blood gas values were measured every 30 minutes to ensure
adequate ventilation. Fetal blood gas values were measured
after placement of instrumentation, immediately before
bypass, every 15 minutes during bypass, and every 15 min-
utes after bypass until completion of the study. At each of
these points hemodynamic data were also recorded.
Data analysis. PVR and systemic vascular resistance
(SVR) were calculated from standard formulas relating resis-
tance to pressure and flow (the Ohm law). Combined ventric-
ular output was calculated as the sum of the ascending aortic
and main pulmonary artery (or pump) flows. Systemic blood
flow (SBF) was estimated as the difference between com-
bined ventricular output and PBF. Data were expressed as
mean ± SD. SPSS version 6.0 (SPSS Inc, Chicago Ill) was
used for all statistical analyses. Differences between groups
were assessed by general factorial analysis of variance.
Paired 2-tailed t tests were used to assess the significance of
changes in hemodynamic variables (with respect to baseline
levels before administration) after acetylcholine, sodium
nitroprusside, and ET-1 were given, both before and after
bypass. The significance of differences between prebypass
and postbypass responses (mean percentages change) to
administration of acetylcholine, nitroprusside, and ET-1 was
also examined by paired 2-tailed t test analysis.
Results
Group 1. Results of prebypass and postbypass inter-
ventions are summarized in Table I and also described.
There were no significant differences in baseline SAP,
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combined ventricular output, PBF, SBF, PVR, or SVR
before administration of the 3 pharmacologic agents,
both before and after bypass.
Acetylcholine. In response to acetylcholine adminis-
tration SAP decreased significantly before and after
bypass. As depicted in Fig 1, PBF increased with both
prebypass and postbypass acetylcholine administration,
although the increase was attenuated after bypass (7%
versus 12% before bypass, P = .04). SBF decreased sig-
nificantly (P = .0005) before bypass but not after
bypass. The difference between prebypass and postby-
pass SBF responses to acetylcholine was significant (P
= .001). PVR decreased significantly after prebypass
and postbypass administration of acetylcholine, but the
PVR decrease was significantly greater before bypass
than after bypass (Fig 1). Alhough SVR did not change
significantly before or after bypass, the difference
between prebypass and postbypass SVR responses to
acetylcholine was significant (18% increase prebypass
versus 7% decrease postbypass; P = .006).
Sodium nitroprusside. SAP decreased significantly
after nitroprusside administration both before and after
bypass. Nitroprusside administration led to a significant
drop in PBF before bypass but not after bypass (Fig 1).
The difference between prebypass and postbypass PBF
responses to nitroprusside was not significant. SBF fell
significantly after both prebypass and postbypass nitro-
prusside administration, but the response was signifi-
cantly greater before bypass than after bypass (P = .01).
As shown in Fig 1, PVR decreased significantly after
prebypass and postbypass nitroprusside administration,
but the PVR responses to nitroprusside before and after
bypass did not differ significantly. Calculated SVR rose
significantly (although by <10%) in response to preby-
pass nitroprusside administration but not postbypass
nitroprusside administration. The difference between
prebypass and postbypass changes after nitroprusside
administration was significant (P = .01).
Endothelin 1. In response to ET-1 administration
there was a small but significant increase in SAP after
bypass but not before bypass. SBF increased signifi-
cantly before and after bypass, and the postbypass
increase was significantly greater than the prebypass
response (P = .04). PBF decreased significantly in
response to ET-1 administration before and after
bypass, but the response was significantly greater after
bypass than before bypass (Fig 1). PVR increased sig-
nificantly after prebypass and postbypass ET-1 admin-
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Table I. Hemodynamic effects of acetylcholine, nitroprusside, and ET-1 administration before and after cardiac
bypass in group 1 fetuses (n = 7)
PVR SVR 
SAP PBF SBF (mm Hg × mL–1 · (mm Hg × mL–1 · 
Intervention and timing (mm Hg) (mL · min–1 · kg–1) (mL · min–1 · kg–1) min–1 · kg–1) min–1 · kg–1)
Acetylcholine, before bypass
Before acetylcholine 59.4 ± 7.9 131.0 ± 27.5 129.3 ± 66.9 0.48 ± 0.14 0.56 ± 0.23
After acetylcholine 52.9 ± 6.2‡ 145.7 ± 25.8‡ 105.6 ± 60.4‡ 0.37 ± 0.09† 0.66 ± 0.34
Acetylcholine, after bypass
Before acetylcholine 60.6 ± 2.8 79.4 ± 22.7 137.9 ± 67.0 0.85 ± 0.39 0.56 ± 0.32
After acetylcholine 55.7 ± 3.9‡ 84.0 ± 22.2† 134.4 ± 64.7 0.73 ± 0.31† 0.52 ± 0.29
Sodium nitroprusside,
before bypass
Before nitroprusside 56.9 ± 3.4 129.9 ± 32.0 117.9 ± 79.6 0.46 ± 0.13 0.67 ± 0.41
After nitroprusside 49.7 ± 2.9‡ 123.6 ± 32.3† 99.1 ± 69.7‡ 0.43 ± 0.12† 0.72 ± 0.44*
Sodium nitroprusside,
after bypass
Before nitroprusside 59.1 ± 4.7 70.1 ± 18.7 147.0 ± 70.9 0.92 ± 0.36 0.49 ± 0.24
After nitroprusside 51.4 ± 4.6‡ 67.2 ± 19.4 135.5 ± 64.1* 0.84 ± 0.32* 0.45 ± 0.19
ET-1, before bypass
Before ET-1 55.9 ± 3.9 133.4 ± 39.1 112.6 ± 70.7 0.46 ± 0.18 0.77 ± 0.62
After ET-1 55.7 ± 4.8 121.8 ± 36.7† 118.7 ± 70.7‡ 0.51 ± 0.21† 0.70 ± 0.55*
ET-1, after bypass
Before ET-1 57.4 ± 4.1 73.0 ± 18.1 145.5 ± 67.3 0.86 ± 0.34 0.47 ± 0.20
After ET-1 59.4 ± 2.8* 38.4 ± 13.1‡ 169.4 ± 72.6† 1.73 ± 0.67‡ 0.40 ± 0.14*
Values are mean ± SD.
*P ≤ .001 relative to preintervention values.
†P ≤ .01 relative to preintervention values.
‡P ≤ .05 relative to preintervention values.
istration (Fig 1), but the postbypass response was
markedly more pronounced (P = .003). ET-1 adminis-
tration caused a significant decrease in SVR both
before and after bypass.
Group 2. In the group of eight fetuses that received
the ET-1 blocker PD 145065, PVR increased from 0.32
± 0.03 mm Hg · mL–1 · min–1 · kg–1 before bypass to
0.41 ± 0.07 mm Hg · mL–1 · min–1 · kg–1 after bypass,
which was significantly less than in control animals
(0.31 ± 0.04 mm Hg · mL–1 · min–1 · kg–1 before bypass
and 0.51 ± 0.14 mm Hg · mL–1 · min–1 · kg–1 after
bypass, P = .01). Similarly, PBF decreased significant-
ly more in control animals (from 184 ± 22 mL · min–1
· kg–1 to 119 ± 20 mL · min–1 · kg–1) than in fetuses
receiving ET-1 receptor blocker (from 178 ± 28 mL ·
min–1 · kg–1 to 146 ± 18 mL/min/kg mL · min–1 · kg–1,
P = .02). These results are depicted in Fig 2. In
response to the bolus of ET-1 administered 60 minutes
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Fig 1. Mean ± SD percentage change in indexed placental blood flow (A) and indexed PVR (B) after acetyl-
choline, sodium nitroprusside, and ET-1 administration before and after fetal cardiac bypass (n = 7). Mean val-
ues are displayed above the columns. Asterisk represents P ≤ .05 and dagger represents P ≤ .01 for paired 2-tailed
t test comparisons between prebypass and postbypass mean percentage changes in PBF or PVR after administra-
tion of acetylcholine or ET-1. Error bars represent SD.
A
B
after bypass, no changes in any of the hemodynamic
variables monitored were seen in fetuses that received
PD 145065, whereas those that had not received the
ET-1 blocker had significantly decreased PBF (from
112 ± 23 mL · min–1 · kg–1 immediately before admin-
istration of ET-1 to 23 ± 11 mL · min–1 · kg–1 10 min-
utes afterward, P < .001) and increased PVR (from 0.55
± 0.03 mm Hg · mL–1 · min–1 · kg–1 to 3.16 ± 1.62 mm
Hg · mL–1 · min–1 · kg–1, P < .001). This difference
between the 2 groups confirms the endothelin receptor
blockade in the fetuses that received PD 145065.
Group 3. Plasma ET-1 level increased significantly
in fetuses placed on cardiac bypass but did not change
in control animals (Table II and Fig 3). PBF decreased
significantly and PVR increased significantly in the 5
fetuses exposed to bypass (Table II). There were no
changes in hemodynamics or serum ET-1 levels in the
4 control fetuses.
Discussion
Fetal cardiac surgery may offer a means of repairing
certain congenital heart defects with better results than
can be achieved after birth.1 To gain surgical access to
the fetal heart, it is necessary to develop a safe and
effective method of fetal cardiac bypass for extracorpo-
real circulatory support. Studies to date have discov-
ered that fetal cardiac bypass is complicated by placen-
tal dysfunction.2-4 As with the systemic inflammatory
response syndrome that occurs after cardiopulmonary
bypass in infants and adults,18 a number of factors have
been implicated in fetal cardiac bypass–related placen-
tal dysfunction, including the fetal stress response,
eicosanoid elaboration, extracorporeal surfaces, and
nonpulsatile flow.2-5,14 Cardiopulmonary bypass in
pediatric patients has been shown to result in elevated
levels of circulating ET-1, and there is evidence that
cardiopulmonary bypass causes endothelial damage.20
However, there are no reported studies of the role of
endothelial factors in peribypass placental dysfunction
or of the placental endothelial response to fetal cardiac
bypass.
It is well known that endothelium-derived relaxing
factors, such as nitric oxide, are important regulators of
placental vascular tone.8-10 Chaudhuri and associates8
demonstrated an endothelium-dependent release of
nitric oxide from human umbilical veins. Others have
shown increased PVR and decreased PBF after selec-
tive inhibition of nitric oxide synthesis with Nw -nitro-L-
arginine in both fetal lambs and isolated human pla-
cental cotyledons.9,10 In this study we indirectly
assessed the effect of fetal cardiac bypass on endothe-
lial nitric oxide production by comparing prebypass
and postbypass vasodilation of the placental vascular
bed by endothelium-dependent and independent mech-
anisms. Acetylcholine, which increases endothelial
nitric oxide production by means of receptor-mediated
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A B
Fig 2. Mean ± SD PBF (A) and PVR (B) before and after bypass in group 2 fetuses that underwent cardiac bypass
with the ET-1 receptor blocker PD 145065 (n = 8) and in fetuses that underwent bypass without PD 145065
(Control, n = 5). PBF is given in milliliters per minute per kilogram and PVR is given in millimeters of mercury
per milliliter per minute per kilogram.
stimulation of nitric oxide synthase, was used as the
endothelium-dependent vasodilator. Sodium nitroprus-
side, which exerts its vasodilatory effect by acting as a
nitric oxide donor, was used as the endothelium-inde-
pendent vasodilator. Because the nitric oxide con-
tributed by these 2 mechanisms acts through a final
common pathway, a comparison of the vasoactive
effects of acetylcholine and nitroprusside may be used
to evaluate the ability of the endothelium to produce
nitric oxide in response to normal stimulatory signals.
Our results demonstrate a selective impairment in
endothelium-dependent vasodilation. After bypass
acetylcholine administration induced significantly
smaller increase in PBF (7% vs 12%, P < .05) and
decrease in PVR (14% vs 20%, P < .05) than it did
before bypass. In contrast, bypass had no effect on the
PBF or PVR response to nitroprusside.
ET-1 is also known to be an important regulator of
placental vascular tone.11-13 Several groups have
demonstrated a dose-dependent increase in PVR in
response to ET-1 administration, a reaction that could
be blocked by inhibition of endothelin-converting
enzyme with phosphoramidon.11,12 In examining the
effects of ET-1 on placental vascular tone, it is impor-
tant to consider its complex vasoactive properties. The
hemodynamic effects of ET-1 are mediated by 2 differ-
ent subtypes of endothelin receptors, ETA and ETB.21
ETA receptors and a subpopulation of ETB receptors
mediate vasoconstriction and are located on vascular
smooth muscle cells, whereas another subpopulation of
ETB receptors mediates vasodilation and is located on
vascular endothelial cells.21 Both ETA and ETB recep-
tors are present in the placenta.22 In this study the most
dramatic difference between prebypass and postbypass
endothelial function was seen with the administration
of ET-1. Before bypass ET-1 decreased PBF by 9% and
increased PVR by 9%. After bypass, however, ET-1
administration resulted in a significantly greater
decrease in PBF (47%; P = .0005) and a significantly
greater rise in PVR (106%; P = .001). Nonspecific
endothelin receptor blockade blunted the hemodynam-
ic response to bypass to a significant degree, and
absence of the PVR and PBF response to exogenous
ET-1 administration in these fetuses confirmed the
endothelin receptor antagonism. Moreover, there was
significant elevation of umbilical venous serum ET-1
level after bypass in group 3 fetuses. Taken together,
these results provide strong evidence in support of a
role for ET-1 in placental dysfunction after fetal cardiac
bypass.
Physiologic antagonism between nitric oxide and ET-
1 has been shown in many regional circulations.23 Our
data suggest that the increase in PVR after fetal bypass
may be multifactorial, related to a combination of
decreased nitric oxide production by the endothelium,
increased circulating levels of ET-1 acting on ETA
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Table II. Placental hemodynamics and ET-1 levels
before and after fetal cardiac bypass
Bypass Control* 
(n = 5) (n = 4)
Umbilical venous serum ET-1 
(pg/mL)
Before bypass 6.3 ± 3.1 3.8 ± 2.7
After bypass or waiting 28.3 ± 10.4† 5.4 ± 1.1
Placental blood flow 
(mL · min–1 · kg–1)
Before bypass 170 ± 28 155 ± 14
After bypass or waiting 127 ± 36† 146 ± 13†
Change from before to after –26 ± 11‡ –6 ± 3
bypass (%)
PVR (mm Hg · mL–1 · 
min–1 · kg–1)
Before bypass 0.33 ± 0.05 0.39 ± 0.10
After bypass or waiting 0.44 ± 0.01† 0.40 ± 0.10
Change from before to after 34 ± 19‡ 2 ± 2
bypass (%)
Data are expressed as mean ± SD.
*Control animals were not placed on bypass but were exposed similar to
bypass fetuses for 30 minutes.
†P ≤ .01 versus values before bypass.
‡P ≤ .001 versus control values.
Fig 3. Mean ± SD umbilical venous serum ET-1 (in
picograms per milliliter) in fetuses that were placed on car-
diac bypass (Bypass, n = 5) and control fetuses that were not
(Control, n = 4).
receptors, and decreased vasodilation through endothe-
lial ETB receptors. Endothelial injury could account for
all these changes; however, more investigation is nec-
essary to determine the specific mechanisms of
endothelial dysfunction after fetal cardiac bypass. As
Champsaur and colleagues6 showed, the addition of
pulsatile flow to the fetal bypass protocol may stimu-
late the release of nitric oxide and the resulting
vasodilatory response, helping to preserve placental
hemodynamics during and after bypass. If the endothe-
lial system can be effectively and safely modulated
with specific inhibitors (unlike the nonspecific
endothelin receptor blocker used in this study) or other
means, such as pulsatile flow or minimization of the
humoral response to the bypass circuit,14 it may be pos-
sible to significantly improve placental function and
fetal outcome after cardiac bypass. In addition, it will
be important to elucidate the relationships among the
endothelial, eicosanoid, cytokine, and adrenergic sys-
tems in producing the comprehensive hemodynamic
response to fetal bypass. Previous studies documented
that inhibition of the cyclo-oxygenase cascade with
indomethacin and inhibition of the fetal stress response
with glucocorticoids can lead to improved hemody-
namics and survival after fetal bypass.2,4 These systems
almost certainly interact with the process of endotheli-
um-mediated placental dysfunction studied in this set
of experiments. The nature of these relationships and
the optimal means of mediating the impairment in pla-
cental dysfunction require further study.
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Discussion
Dr Edward D. Verrier (Seattle, Wash). In the past your
group has shown that indomethacin impairs prostaglandins,
and prostaglandins were previously postulated as the primary
mechanism of these changes in PVR. How do the 2 stories
work together? If you administer indomethacin, is that addi-
tive with the endothelin effects?
The second corollary question is about the relationship
between nitric oxide and endothelin. Have you done studies
that would do things to enhance nitric oxide synthase to
maintain the vasodilatory response? What is the relationship
between that and endothelin?
Dr McElhinney. One of the big questions that we are try-
ing to get at now is the relationship among the various factors
involved in postbypass placental dysfunction. We have found
a number of factors that are associated with worse outcome
and also a number of interventions that can lead to improved
outcome. One of the main objectives that we are currently
pursuing is trying to rationalize all these different mecha-
nisms into a single model and determine what sort of inter-
ventions can result in optimal improvement. In response to
your question, we do not really know how the endothelial and
prostaglandin systems interact, although we are fairly certain
that they are independent to some degree in this model.
With respect to your second question regarding the interac-
tion between nitric oxide and ET-1, last year Champsaur and
associates presented the results of an experiment in which
they looked at the effects of pulsatile flow on nitric oxide
activity in a fetal cardiac bypass model. They showed that
pulsatile perfusion does in fact lead to improved placental
hemodynamics, most likely as a result of stimulation of nitric
oxide synthase. We know that nitric oxide normally antago-
nizes ET-1 in the fetoplacental circulation, and we also know
that ET-1 acts differently according to the type of receptor on
which it is working. There are ETA and ETB receptor sub-
types that are located on both endothelial and smooth muscle
cells, have differing affinities for ET-1, and exert both vaso-
constrictive and vasodilatory effects according to where they
are located. We used a nonspecific receptor blocker that
blocks both ETA and ETB receptor subtypes and thus proba-
bly exerted its effects through multiple mechanisms. That is
another area that we are trying to work out further.
Dr Renato Assad (Sao Paulo, Brazil). I have some concerns
regarding pulmonary vascular resistance during fetal cardiac
bypass. We know that pulmonary blood flow to the fetal lungs
is about 8% of fetal cardiac output. During fetal cardiac bypass
there is a shift of blood away from the placenta toward the
lung. I have 2 questions regarding pulmonary blood flow and
placental function during fetal cardiac bypass. First, did you
measure pulmonary blood flow in this protocol? Second, did
you assess placental function during and after fetal cardiac
bypass, with and without the ET-1 receptor blocker?
Dr McElhinney. We did not measure pulmonary blood
flow directly. We measured combined ventricular output with
a perivascular flow probe on the ascending aorta summated
with pump flow during bypass. After bypass we had a
perivascular flow probe on the main pulmonary artery. If you
are asking about placental function in terms of oxygenation
and acid-base status, we did assess this. Oxygenation and
acid-base status paralleled placental hemodynamics.
Dr Frank W. Sellke (Boston, Mass). Altered endothelial
function after bypass has been demonstrated by many differ-
ent groups. You have nicely extended this to the fetal circula-
tion. I think the most interesting aspect of this work is the
markedly hypercontractile effect in response to ET-1, which
does not appear to me to be due to altered basal release of
nitric oxide. The response simply seems to be too profound
for that. To my way of thinking, it has to be some other alter-
ation in another pathway, for example the cyclo-oxygenase
pathway. The inducible cyclo-oxygenase level can be rapidly
upwardly regulated and induced. You can see fairly marked
increases in messenger RNA in relatively short periods after
such pathologic interventions as bypass and ischemia.
Furthermore, ET-1 is known to cause the release of nitric
oxide. Do you think there may be some relationship there?
Dr McElhinney. Yes, I do think that there probably is a
relationship between the nitric oxide and cyclo-oxygenase
systems, and that is among the questions that we are hoping
to answer. It has been shown in the past, by Dr Hanley and his
group, that inhibition of the cyclo-oxygenase pathway
markedly improves postbypass placental function. As I said
earlier, one of the issues on which we are focusing now is try-
ing to understand how these different systems interact and
whether there is a final common pathway or they are parallel
systems that are exerting separate effects.
With respect to the effect of ET-1, the placental circulation
is thought to be maximally dilated in its basal state. Thus the
addition of nitric oxide or any other vasodilator to the pla-
cental circulation in a nonconstricted state does not result in
much vasodilation. This is an important consideration in
looking at the vasoconstrictor response to ET-1 in this case. I
do not have a good answer to your questions at this point, but
you have pinpointed an important direction in which we hope
to take our work.
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